A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab (Q28282330)

Journal of Dermatological Treatment

Europe PubMed Central

title

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab (English)

0 references

0 references

N Scheinfeld

1

0 references

language of work or name

English

0 references

publication date

September 2004

0 references

published in

0 references

volume

15

0 references

issue

5

0 references

page(s)

280-94

0 references

cites work

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1080/09546630410017275

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

21 April 2017

1 reference

https://api.crossref.org/works/10.1080/09546630410017275

Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives

21 April 2017

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Comorbid conditions in patients with rheumatic diseases: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Kaposi's sarcoma associated with tumour necrosis factor alpha neutralising therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Shingles following infliximab infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Severe herpes zoster after infliximab infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFalpha-antibody and methotrexate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Septic arthritis caused by Moraxella catarrhalis associated with infliximab treatment in a patient with undifferentiated spondarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Miliary tuberculosis after infliximab therapy in Lebanon

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Tuberculous tonsillitis in a patient receiving etanercept treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

The role of tumor necrosis factor alpha blockade in the treatment of congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Infliximab treatment of rheumatoid arthritis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Onset of multiple sclerosis associated with anti-TNF therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Bilateral anterior toxic optic neuropathy and the use of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Infliximab-associated retrobulbar optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Etanercept-induced systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

A lupus-like syndrome associated with infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Psoriasiform eruption induced by infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Red man syndrome and infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Lung injury linked to etanercept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Silent thyroiditis associated with etanercept in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

Skin reaction to adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017275

10.1080/09546630410017275

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

15370396

1 reference

Consolidated OpenCitations Corpus – April 2017